Mineralys Therapeutics, Inc. (MLYS) Form 8-K — Oct 19, 2026
Mineralys Therapeutics appointed Kristine Peterson and Lonnel Coats to its Board of Directors effective October 19, 2026, expanding the board from seven to nine members. Ms. Peterson joins the Audit Committee as a Class I director, while Mr. Coats joins the Compensation Committee as a Class II director; both were determined to satisfy Nasdaq independence requirements.
Key figures
- Board size after
- 9
- Board size before
- 7
- Director rsu grant shares each
- 12400
- Director option grant shares each
- 16600
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.